GSK Faces New York Suit Over Paxil: Publish Or Punish?
Executive Summary
GlaxoSmithKline's failure to publish pediatric safety study results for its antidepressant Paxil (paroxetine) is one basis of fraud allegations lodged against the company by New York Attorney General Eliot Spitzer
You may also be interested in...
Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products
Bristol Vanlev Settlement Does Not Include Pre-Marketing Results Disclosure
A settlement over allegations that Bristol-Myers Squibb misled investors about its investigational antihypertensive Vanlev does not establish disclosure guidelines for investigational products
PhRMA Expects Study Results Database To Be Fully Populated By October
The Pharmaceutical Research & Manufacturers of America expects full participation from all association members in the PhRMA-sponsored database ClinicalStudyResults.org by October